XARELTO® (rivaroxaban) for US HCP

XARELTO® for US Healthcare Professionals

Hello and welcome. This is the official XARELTO® for US HCPs page! This page is dedicated to helping you learn more about how XARELTO®, a latest-generation blood thinner, can reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF); treat deep vein thrombosis (DVT) and/or pulmonary embolism (PE

); reduce the risk of DVT and/or PE in patients at continued risk for recurrent DVT and/or PE after completion of initial treatment lasting at least 6 months; be used for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery; be used for the prophylaxis of venous thromboembolism (VTE) and VTE-related death during hospitalization and post hospital discharge in adult patients admitted for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE, and not at high risk of bleeding; and, in combination with aspirin, to reduce the risk of major cardiovascular events (cardiovascular [CV] death, myocardial infarction [MI], and stroke) in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD). INDICATIONS

XARELTO® (rivaroxaban) is indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (AF). There are limited data on the relative effectiveness of XARELTO® and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well controlled. XARELTO® is indicated for the treatment of deep vein thrombosis (DVT). XARELTO® is indicated for the treatment of pulmonary embolism (PE). XARELTO® is indicated for the reduction in the risk of recurrence of DVT and/or PE in adult patients at continued risk for recurrent DVT and/or PE after completion of initial treatment lasting at least 6 months. XARELTO® is indicated for the prophylaxis of DVT, which may lead to PE in adult patients undergoing knee or hip replacement surgery. XARELTO® is indicated for the prophylaxis of venous thromboembolism (VTE) and VTE-related death during hospitalization and post hospital discharge in adult patients admitted for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE, and not at high risk of bleeding. XARELTO®, in combination with aspirin, is indicated to reduce the risk of major cardiovascular events (cardiovascular death, myocardial infarction, and stroke) in adult patients with coronary artery disease (CAD). XARELTO®, in combination with aspirin, is indicated to reduce the risk of major thrombotic vascular events (myocardial infarction, ischemic stroke, acute limb ischemia, and major amputation of a vascular etiology) in adult patients with peripheral artery disease (PAD), including patients who have recently undergone a lower extremity
revascularization procedure due to symptomatic PAD. XARELTO® is indicated for the treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years after at least 5 days of initial parenteral anticoagulant treatment. XARELTO® is indicated for
thromboprophylaxis in pediatric patients aged 2 years and older with congenital heart disease who have undergone the Fontan procedure.

_______________________________________________________________

Please keep in mind: Content from this XARELTO® page is meant for US healthcare professionals only. We may share links to third-party websites that we think you may find useful. However, Janssen Pharmaceuticals, Inc., does not endorse, and is not responsible for, the content you may find on those websites. For 1st Party Custom Audiences: In order to provide you with relevant information about XARELTO® that meets your professional needs, XARELTO® has provided your contact information to Facebook. This means you could see Facebook advertisements for XARELTO®. If you would prefer not to receive these advertisements, you may opt out, by clicking the ellipses in the right hand corner of the advertisement. For 3rd Party Custom Audiences: In order to provide you with relevant information about XARELTO® that meets your professional medical needs, XARELTO® has provided your contact information in an encrypted and anonymous format to Facebook. If you prefer not to receive these advertisements, you may opt out by clicking on the ellipses in the right hand corner of the advertisement. MEDICAL INFORMATION CENTER
Thank you for your interest in contacting Janssen Pharmaceuticals, Inc. Please note that we can only provide information about products marketed within the United States, and must refer international inquiries to our affiliates. For additional information, please contact Janssen Medical Information by using one of the following methods:

Phone: Call 1-800-JANSSEN (1-800-526-7736) Email: Submit questions via our askjanssenmedinfo.com site

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/safety/medwatch or call 1-800-FDA-1088.